Haemonetics (HAE) Gross Profit (2009 - 2026)

Haemonetics has reported Gross Profit for 18 years, with the latest figure at $198.2 million in Q1 2026.

• For the quarter ending Q1 2026, Gross Profit rose 2.67% year-over-year to $198.2 million; the trailing twelve-month figure through Mar 2026 stood at $787.6 million (up 5.16% YoY), and the FY2026 full-year result was $787.6 million, up 5.16% from the prior year.
• Gross Profit for Q1 2026 stood at $198.2 million, down from $202.4 million in the prior quarter.
• The five-year high for Gross Profit was $202.4 million in Q4 2025, with the low at $136.3 million in Q2 2022.
• Average Gross Profit over 5 years is $173.2 million, with a median of $175.4 million recorded in 2024.
• Year-over-year, Gross Profit surged 66.63% in 2022 and climbed 2.67% in 2026.
• Tracing HAE's Gross Profit over 5 years: stood at $158.7 million in 2022, then gained by 12.07% to $177.9 million in 2023, then grew by 8.82% to $193.5 million in 2024, then climbed by 4.57% to $202.4 million in 2025, then dropped by 2.06% to $198.2 million in 2026.
• The last three Gross Profit figures came in at $198.2 million (Q1 2026), $202.4 million (Q4 2025), and $194.7 million (Q3 2025), per Business Quant data.

Peer Comparison